EBMT – Medxy AI

Outcomes of Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome in Young Adults: Insights from the EBMT Chronic Malignancies Working Party

By MedXY 10/08/2026

This retrospective study evaluates survival outcomes and risk factors associated with allogeneic hematopoietic cell transplantation in young adults (18-40 years) with myelodysplastic syndrome, revealing encouraging survival rates and highlighting critical prognostic variables for personalized transplant strategies.

Hematology-Oncology news Public Health

EBMT Crosses One Million Transplants as Allogeneic HCT and CAR-T Reach New Highs in European Cellular Therapy

By MedXY 05/30/2026

The 2024 EBMT activity report marks a major cellular therapy milestone, showing record allogeneic HCT, continued CAR-T expansion, and persistent disparities in donor use, pediatric activity, and country-level access.

Hematology-Oncology news

The 2024 EBMT Activity Report: Crossing One Million HCTs and 20,000 CAR-T, a Landmark in Cellular Therapy

By MedXY 05/30/2026

EBMT’s 2024 report marks over one million reported stem cell transplants and continued rapid CAR-T growth, highlighting shifts in indications, donor use, and access across Europe.